Marc Tessier-Lavigne leaves Pfizer board
This article was originally published in Scrip
Executive Summary
Dr Marc Tessier-Lavigne has stepped down from Pfizer's board of directors – effective 14 May 2015. His decision is coincident with the launch of Denali, a new biotechnology company focused on developing effective therapies for neurodegenerative diseases. Dr Tessier-Lavigne is a co-founder of Denali, and he will serve as chair of the company. Dr Tessier-Lavigne was appointed to Pfizer's board in December 2011, and most recently he was a member of the regulatory and compliance committee and science and technology committee.